<?xml version="1.0" encoding="UTF-8"?>
<p>AZM is generally well tolerated, the most common side effect being diarrhoea,
 <xref rid="rmv2163-bib-0029" ref-type="ref">
  <sup>29</sup>
 </xref> it is contraindicated in pregnancy and known hypersensitivity. Whilst there have been concerns about cardiovascular risk, huge epidemiological studies suggest these are very small effects (eg, 47 extra deaths/million prescriptions) or perhaps no effect when corrected for confounding,
 <xref rid="rmv2163-bib-0134" ref-type="ref">
  <sup>134</sup>
 </xref> and a Cochrane review of 183 trials found no evidence of an increase in cardiac disorders with macrolides (OR 0.87).
 <xref rid="rmv2163-bib-0135" ref-type="ref">
  <sup>135</sup>
 </xref> Concerns have been raised about the potential interactions between HCQ and AZM increasing risk of side effects. It should be used in caution in those receiving some other drugs including fluoroquinolones such as moxifloxacin and levofloxacin, and in patients with ongoing proarrhythmic conditions, and QT prolongation was more frequent in people with COVID‚Äê19 receiving HCQ (14.6%) or the combination of HCQ and AZM (14.7%) than standard care (1.7%), an effect likely purely attributable to the HCQ.
 <xref rid="rmv2163-bib-0133" ref-type="ref">
  <sup>133</sup>
 </xref>
</p>
